NDA 210115 · Astellas
Prograf
Tacrolimus · Oral
OrphanLast checked: Nov 20, 2026Latest source record: Sep 14, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
May 24, 2018
Approved uses
2
Original approval plus efficacy supplements
Registered trials
1,405
234 Phase 3, 122 recruiting
FAERS reports
155,512
139,657 serious, 25,602 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: MALIGNANCIES AND SERIOUS INFECTIONS Increased risk for developing serious infections and malignancies with PROGRAF or other immunosuppressants that may lead to hospitalization or death. ( 5.1 , 5.2 ) WARNING: MALIGNANCIES AND SERIOUS INFECTIONS See full prescribing information for complete boxed warning. Increased risk for developing serious infections and malignancies with PROGRAF or other immunosuppressants that may lead to hospitalization or death. ( 5.1 , 5.2 )
What it is approved for
From the label in effect Aug 25, 2023.
PROGRAF is a calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. ( 1.1 ) 1.1 Prophylaxis of Organ Rejection in Kidney, Liver, Heart, or Lung Transplant PROGRAF ® is indicated for the prophylaxis of organ rejection, in adult and pediatric patients receiving allogeneic kidney transplant [see Clinical Studies ( 14.1 )], liver transplant [see Clinical Studies ( 14.2 )], heart transplant [see Clinical Studies ( 14.3 )], or lung transplant [see Clinical Studies ( 14.4 )] in combination with other immunosuppressants.
Mechanism: Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin (a ubiquitous mammalian intracellular enzyme) is then formed, after which the phosphatase activity of calcineurin is inhibited. Such inhibition prevents the dephosphorylation and translocation of various factors such as the nuclear factor of activated T-cells (NF-AT), and nuclear factor kappa-light-chain enhancer of activated B-cells (NF-κB). Tacrolimus inhibits the expression and/or production of several cytokines that include interleukin (IL)-1 beta, IL-2, IL-3, IL-4,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 16, 2021 Supplement 5 · Efficacy · priority review OrphanLabelLetterReview
- May 24, 2018 Original approval · Type 3 - New Dosage Form OrphanLabelLetterReview
2 products under this application
- PROGRAF · TACROLIMUS EQ 0.2MG BASE/PACKET · FOR SUSPENSION, ORAL · Prescription
- PROGRAF · TACROLIMUS EQ 1MG BASE/PACKET · FOR SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tacrolimus" as an intervention, any sponsor and status, largest first.
- Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP PancreatitisPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT05252754 · 4,874 participants (planned) · Start Jan 18, 2023 · Primary completion Dec 2026
Drug: Tacrolimus capsule; Placebo and 1 more · For: Post-ERCP Acute Pancreatitis
Sites: Baltimore, Maryland; Hyderabad, India; Kolkata, India · 5 sites in all
- Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01950819 · 2,037 participants · Start Dec 3, 2013 · Primary completion Feb 1, 2017
Drug: Induction therapy; Corticosteroids and 2 more · For: End Stage Renal Disease (ESRD); Chronic Kidney Disease (CKD); Hemodialysis and 2 more
Sites: Birmingham, Alabama; Loma Linda, California; Los Angeles, California · 184 sites in all
- A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney RejectionPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00717470 · 1,252 participants · Start May 14, 2008 · Primary completion Mar 2, 2010
Drug: Prograf®; Advagraf® and 3 more · For: Kidney Transplantation
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Innsbruck, Austria · 110 sites in all
- Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney TransplantationPivotal-lookingCompleted
Hospital do Rim e HipertensãoAcademic, hospital or other
NCT03468478 · 1,209 participants · Start Jun 18, 2017 · Primary completion Mar 18, 2021
Drug: Sirolimus; Everolimus and 1 more · For: Kidney Transplant Infection
Sites: São Paulo, Brazil
- A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without SteroidsPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT01304836 · 1,166 participants · Start Jan 22, 2011 · Primary completion May 22, 2013
Drug: Advagraf; Mycophenolate Mofetil and 2 more · For: Kidney Transplantation
Sites: Perth, Australia; Sydney, Australia; Brussels, Belgium · 100 sites in all
- Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised TrialPivotal-lookingRecruiting
University of EdinburghAcademic, hospital or other
NCT04302870 · 1,150 participants (planned) · Start Feb 27, 2020 · Primary completion Dec 2030
Drug: Memantine Hydrochloride Oral Solution; Trazodone Hydrochloride oral solution and 4 more · For: Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Sites: Portadown, United Kingdom; Aberdeen, United Kingdom; Birmingham, United Kingdom · 22 sites in all
- To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)Pivotal-lookingCompleted
Glenmark Pharmaceuticals Ltd. IndiaIndustry
NCT02601703 · 1,110 participants · Start Aug 2015 · Primary completion Oct 2016
Drug: Tacrolimus Ointment 0.1%; Protopic® ointment, 0.1% and 1 more · For: Atopic Dermatitis
Sites: Tempe, Arizona; Anaheim, California; Bell Gardens, California · 60 sites in all
- Fixed Dose MMF vs Concentration Controlled MMF After Renal TransplantationPivotal-lookingCompleted
Erasmus Medical CenterAcademic, hospital or other
NCT00166244 · 901 participants · Start May 2003 · Primary completion Mar 2005
Drug: Mycophenolate Mofetil · For: De Novo Renal Transplant Recipient.
Sites: New Lambton, Australia; Brisbane, Australia; Clayton, Australia · 67 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use15,345
- drug ineffective10,482
- product use in unapproved indication6,396
- drug interaction6,373
- acute kidney injury6,111
- diarrhoea5,893
- transplant rejection4,902
- death4,875
- pyrexia4,864
- cytomegalovirus infection4,599
- pneumonia4,567
- toxicity to various agents3,914
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 699 |
| 2005 | 875 |
| 2006 | 913 |
| 2007 | 1,485 |
| 2008 | 1,997 |
| 2009 | 2,169 |
| 2010 | 2,343 |
| 2011 | 3,918 |
| 2012 | 4,663 |
| 2013 | 3,853 |
| 2014 | 4,552 |
| 2015 | 5,030 |
| 2016 | 6,022 |
| 2017 | 8,087 |
| 2018 | 10,994 |
| 2019 | 10,666 |
| 2020 | 12,133 |
| 2021 | 11,473 |
| 2022 | 11,897 |
| 2023 | 13,254 |
| 2024 | 14,306 |
| 2025 | 14,189 |
| 2026 | 9,986 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Prograf* (Tacrolimus)
2024 spending
$4.0M
Beneficiaries
865
4,634 claims
Per beneficiary
$4,625
$5.93 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $7,621,148 |
| 2021 | $6,440,835 |
| 2022 | $5,538,435 |
| 2023 | $4,911,768 |
| 2024 | $4,000,824 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical anti-inflammatory treatments for eczema: network meta-analysis.
Lax SJ, Van Vogt E, Candy B, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data.
Webster AC, Woodroffe RC, Taylor RS, et al. · BMJ 2005 · Comparative Study, Meta-Analysis
- A Comprehensive Mixed-Method Approach to Characterize the Source of Diurnal Tacrolimus Exposure Variability in Children: Systematic Review, Meta-analysis, and Application to an Existing Data Set.
Leino AD, Magee JC, Kershaw DB, et al. · J Clin Pharmacol 2024 · Systematic Review, Meta-Analysis
- Effect of CYP3A5*1 expression on tacrolimus required dose after liver transplantation: A systematic review and meta-analysis.
Hendijani F, Azarpira N, Kaviani M · Clin Transplant 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Effects of CYP3A5 polymorphisms on tacrolimus pharmacokinetics in pediatric kidney transplantation: a systematic review and meta-analysis of observational studies.
Zong YP, Wang ZJ, Zhou WL, et al. · World J Pediatr 2017 · Meta-Analysis, Systematic Review
- Topical Anti-Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta-Analysis.
Lax SJ, Van Vogt E, Candy B, et al. · Clin Exp Allergy 2024 · Systematic Review, Network Meta-Analysis
Sponsor: Astellas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.